14:04:15 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-30 Kvartalsrapport 2024-Q2
2024-04-12 X-dag ordinarie utdelning TRMED 0.00 NOK
2024-04-11 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-04-27 X-dag ordinarie utdelning TRMED 0.00 NOK
2023-04-26 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-08-31 Kvartalsrapport 2022-Q2
2022-04-29 X-dag ordinarie utdelning TRMED 0.00 NOK
2022-04-28 Årsstämma 2022
2022-03-01 Bokslutskommuniké 2021
2021-11-18 15-10 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-16 X-dag ordinarie utdelning TRMED 0.00 NOK
2021-03-22 Extra Bolagsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-10-21 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-06-11 X-dag ordinarie utdelning TRMED 0.00 NOK
2020-06-10 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-27 Bokslutskommuniké 2019
2019-11-19 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-04-26 X-dag ordinarie utdelning TRMED 0.00 NOK
2019-04-25 Årsstämma 2019
2019-02-18 Extra Bolagsstämma 2019
2018-08-22 Kvartalsrapport 2018-Q2
2018-05-31 X-dag ordinarie utdelning TRMED 0.00 NOK
2018-05-30 Kvartalsrapport 2018-Q1
2018-05-30 Årsstämma 2018
2018-02-27 Bokslutskommuniké 2017
2017-12-20 Extra Bolagsstämma 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-26 X-dag ordinarie utdelning TRMED 0.00 NOK
2017-05-24 Kvartalsrapport 2017-Q1
2017-05-24 Årsstämma 2017
2017-02-28 Bokslutskommuniké 2016
2016-11-23 Kvartalsrapport 2016-Q3
2016-10-12 Extra Bolagsstämma 2016
2016-08-24 Kvartalsrapport 2016-Q2
2016-05-31 Kapitalmarknadsdag 2016
2016-05-20 X-dag ordinarie utdelning TRMED 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-19 Kvartalsrapport 2016-Q1
2016-02-26 Bokslutskommuniké 2015
2015-11-17 Kapitalmarknadsdag 2015
2015-10-21 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-27 Kvartalsrapport 2015-Q1
2015-03-09 Årsstämma 2015
2014-11-12 Extra Bolagsstämma 2014

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Thor Medical är ett läkemedelsbolag. Bolaget specialiserar sig inom utveckling av antikroppsläkemedel för behandling utav hematologisk cancer. Störst specialisering återfinns inom precisionsterapi som används i den kliniska fasen. Övriga sjukdomar som behandlas är non-hodgkins lymfom (NHL). Bolaget grundades under 2009 och har sitt huvudkontor i Oslo, Norge.
2024-06-06 08:00:05
6.6.2024 08:00:01 CEST | Thor Medical ASA | Non-regulatory press releases

Oslo, Norway, 6 June 2024: Thor Medical and Steenkampskraal Holdings Limited in
South Africa have signed a Memorandum of Understanding for feedstock supply and
technology cooperation. The ambition is to enter into a long-term partnership
agreement for supply of feedstock as part of the Thor Medical's strategy of
developing multiple feedstock suppliers.

The Steenkampskraal Monazite Mine in the Western Cape is considered to have
among the highest concentration of rare earth elements and thorium globally. The
mine's abundant resources of natural thorium are sufficient to meet the global
demand for medical isotopes from its decay for the foreseeable future. The plan
is to leverage Thor Medical's expertise to efficiently produce valuable
alpha-emitters for use in next generation cancer treatment from feedstock from
Steenkampskraal's mineral resources.

"The cooperation with Steenkampskraal can support Thor Medical's ambitions for
the planned industrial-scale production to meet the growing demand for medical
isotopes globally. We look forward to developing partnership agreements with
Steenkampskraal as we build our network of suppliers," says Alf Bjørseth, CEO of
Thor Medical.

The Steenkampskraal Monazite Mine is a fully licensed to operate mining project
and is compliant with all necessary regulatory requirements from, inter alia the
Department of Mineral Resources and Energy, the National Nuclear Regulator, and
the Department of Water and Sanitation. The mine has already commenced with
refurbishment and the start-up of the construction is targeted by end of 2024.
Production of thorium is targeted by end of 2025.



About Thor Medical

Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.

About Steenkampskraal

Steenkampskraal Monazite Mine aims to become a leading producer of rare earth
elements (REEs) and thorium, specifically focusing on monazite extraction.
Located in South Africa, the mine boasts significant deposits of monazite, a
mineral rich in REEs essential for various industries such as electronics,
renewable energy, and defense. Steenkampskraal's business strategy emphasizes
sustainable mining practices, technological innovation, and strategic
partnerships to ensure long-term success.

CONTACTS

* Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.no

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/3180/4614/Download%20announcement
%20as%20PDF.pdf